(OTC: KKUR) ChromoCure to Acquire $25 Million in IP and Technology for Cancer Detection
April 16 2010 - 7:30AM
Marketwired
ChromoCure Inc. (PINKSHEETS: KKUR) announced today it has signed a
Letter of Intent with Genome Research Group (GRG). Under the terms
of the Agreement, ChromoCure will acquire and merge with GRG and
combine the Company's operations and assets with all GRG
Intellectual Property (IP) assets and operations.
The merger transaction is valued in excess of $25,000,000 and
results in significant increases to shareholder equity and
reductions in long-term liabilities. The Company had recently
announced a Technology Exchange and Collaboration Agreement with
GRG, and through the initial integration phase, determined that
joining forces and merging technology and operations would be of
mutual benefit in advancement of their shared objective as a
focused Cancer Therapy and Cure Research & Development
organization.
GRG's advanced Therapeutic Modeling Protocols, together with
ChromoCure's landmark Chromosomal Scanning Technology, further
strengthens the Company's leadership in Cancer Detection.
For More Information on ChromoCure please visit:
www.chromocure.com.
For More Information on Genome Research Group please visit:
www.genomeresearchgroup.com.
Other active stocks are Akorn Inc. (NASDAQ: AKRX), Forest
Laboratories Ltd., (NYSE: FRX) and Pfizer Inc. (NYSE: PFE).
Information, opinions and analysis contained herein are based on
sources believed to be reliable, but no representation, expressed
or implied, is made as to its accuracy, completeness or
correctness. The opinions contained herein reflect our current
judgment and are subject to change without notice. We accept no
liability for any losses arising from an investor's reliance on or
use of this report. This report is for information purposes only,
and is neither a solicitation to buy nor an offer to sell
securities. A third party has hired and paid IO News Wire twelve
hundred and ninety five dollars for the publication and circulation
of this news release. Certain information included herein is
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning manufacturing, marketing, growth, and
expansion. Such forward-looking information involves important
risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein. We
have no ownership of equity, no representation; do no trading of
any kind and send no faxes or emails.
Contact: Eric Jensen Company: IONEWSWIRE.COM Phone:
1-516-942-4910
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2023 to Aug 2024